Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease

• Status: Active, not recruiting
• Trial end date: 2021-12-30

Summary

To assess the tolerability of the costimulation blocking agent abatacept (CTLA4-Ig) when added to the standard graft versus host disease (GVHD) prophylaxis regimen of a calcineurin inhibitor and methotrexate in patients receiving early alemtuzumab followed by fludarabine, thiotepa, melphalan, and alemtuzumab for conditioning.

• Phase: Phase 1

Details

• Lead Sponsor: Monica Bhatia
• Treatments: Abatacept; Acetaminophen; Alemtuzumab; Calcineurin Inhibitors; Cyclosporine; Cyclosporins; Diphenhydramine; Fludarabine; Fludarabine phosphate; Melphalan; Meperidine; Methotrexate; Methylprednisolone; Methylprednisolone acetate; Methylprednisolone Hemisuccinate; Mycophenolic Acid; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate; Promethazine; Sirolimus; Tacrolimus; Thiotepa; Thymoglobulin; Vidarabine